These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32420002)

  • 21. [A case of neutropenia and agranulocytosis induced by clozapine. The importance of a drug surveillance program for their early detection].
    Alfaro J; Berdichevsky E; Conte G; Tellez C
    Rev Med Chil; 1994 Jun; 122(6):694-8. PubMed ID: 7732216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs.
    Sarpatwari A; Mitra-Majumdar M; Bykov K; Avorn J; Woloshin S; Toyserkani GA; LaCivita C; Manzo C; Zhou EH; Pinnow E; Dal Pan GJ; Gagne JJ; Huybrechts KF; Feldman WB; Chin K; Kesselheim AS
    Drug Saf; 2021 Jul; 44(7):743-751. PubMed ID: 33904111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does switching to another antipsychotic in patients with clozapine-associated granulocytopenia solve the problem? Case series of 18 patients.
    Coşar B; Taner ME; Eser HY; Altınöz AE; Tarhan R
    J Clin Psychopharmacol; 2011 Apr; 31(2):169-73. PubMed ID: 21346615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of risk evaluation and mitigation strategies in oncology: summary of the oncology risk evaluation and mitigation strategies workshop.
    Frame JN; Jacobson JO; Vogel WH; Griffith N; Wariabharaj D; Garg R; Zon R; Stephens CL; Bialecki AM; Bruinooge SS; Allen SL
    J Oncol Pract; 2013 Mar; 9(2):e24-39. PubMed ID: 23814522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer?
    Brooks MJ
    Mayo Clin Proc; 2014 Dec; 89(12):1673-84. PubMed ID: 25441401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the potential effect of polypharmacy on the hematologic profiles of clozapine patients.
    Shuman MD; Trigoboff E; Demler TL; Opler LA
    J Psychiatr Pract; 2014 Jan; 20(1):50-8. PubMed ID: 24419309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Risk minimization evolution of agranulocytosis caused by the administration of pharmaceutical products containing Clozapine in Argentina].
    Bergman M; Bignone I; Bisio A; Bologna V; Sabatini A
    Vertex; 2011; 22(96):94-7. PubMed ID: 21977603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clozapine-induced blood dyscrasias in Saudi Arab patients.
    Abanmy NO; Al-Jaloud A; Al-Jabr A; Al-Ruwaisan R; Al-Saeed W; Fatani S
    Int J Clin Pharm; 2014 Aug; 36(4):815-20. PubMed ID: 24917217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clozapine-induced agranulocytosis in Japan: Changes in leukocyte/neutrophil counts before and after discontinuation of clozapine.
    Matsui K; Ishibashi M; Kawano M; Oshibuchi H; Ishigooka J; Nishimura K; Inada K
    Hum Psychopharmacol; 2020 Jul; 35(4):e2739. PubMed ID: 32420645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. White paper on designing a risk evaluation and mitigation strategies (REMS) system to optimize the balance of patient access, medication safety, and impact on the health care system.
    American Pharmacists Association
    J Am Pharm Assoc (2003); 2009; 49(6):729-43. PubMed ID: 19926553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maximizing clozapine utilization while minimizing blood dyscrasias: evaluation of patient demographics and severity of events.
    Demler TL; Morabito NE; Meyer CE; Opler L
    Int Clin Psychopharmacol; 2016 Mar; 31(2):76-83. PubMed ID: 26565383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hematologic effects of clozapine: evaluation of the international experience].
    Lamarque V
    Encephale; 1995 Jun; 21 Spec No 3():59-60. PubMed ID: 7628344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The incidence of clozapine-induced leukopenia in patients with schizophrenia at Srinagarind Hospital.
    Maskasame S; Krisanaprakornkit T; Khiewyoo J
    J Med Assoc Thai; 2007 Oct; 90(10):2175-80. PubMed ID: 18041439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Case of Sudden Very Late Onset of Severe Clozapine-induced Agranulocytosis Following an Influenza Vaccine.
    Jean S; Romain L; Florvil S; Heyliger FG; Mandal A
    Cureus; 2019 May; 11(5):e4682. PubMed ID: 31328073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.
    Slevin KA; Ashburn MA
    J Opioid Manag; 2011; 7(2):109-15. PubMed ID: 21561034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clozapine Rechallenge After Neutropenia or Leucopenia.
    Prokopez CR; Armesto AR; Gil Aguer MF; Balda MV; Papale RM; Bignone IM; Daray FM
    J Clin Psychopharmacol; 2016 Aug; 36(4):377-80. PubMed ID: 27232877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A descriptive study of 10-year clozapine use from the nationwide database in Japan.
    Toyoda K; Hata T; Yamauchi S; Kinoshita S; Nishihara M; Uchiyama K; Inada K; Kanazawa T
    Psychiatry Res; 2021 Mar; 297():113764. PubMed ID: 33567393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system.
    Fahmy AI; Mekkawy MA; Abou-Ali A
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):175-181. PubMed ID: 30738497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.